Marksans Pharma Limited (MARKSANS.NS)
INR 314.2
(-1.83%)
INR 314.2
(-1.83%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 21.77 Billion INR | 17.56% |
| 2022 | 18.52 Billion INR | 25.13% |
| 2021 | 14.8 Billion INR | 8.17% |
| 2020 | 13.68 Billion INR | 21.17% |
| 2019 | 11.29 Billion INR | 14.38% |
| 2018 | 9.87 Billion INR | 8.18% |
| 2017 | 9.12 Billion INR | 18.97% |
| 2016 | 7.67 Billion INR | -14.12% |
| 2015 | 8.93 Billion INR | 12.13% |
| 2014 | 7.96 Billion INR | 26.46% |
| 2013 | 6.29 Billion INR | 43.7% |
| 2012 | 4.38 Billion INR | 23.31% |
| 2011 | 3.55 Billion INR | 16.45% |
| 2010 | 3.05 Billion INR | -15.04% |
| 2009 | 3.59 Billion INR | -0.21% |
| 2008 | 3.6 Billion INR | 36.44% |
| 2007 | 2.63 Billion INR | 9.07% |
| 2006 | 2.41 Billion INR | -18.63% |
| 2005 | 2.97 Billion INR | 17.6% |
| 2004 | 2.52 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 5.9 Billion INR | 5.47% |
| 2023 Q2 | 5.31 Billion INR | 6.24% |
| 2023 Q3 | 5.86 Billion INR | 10.33% |
| 2023 Q1 | 5 Billion INR | 2.89% |
| 2023 FY | 21.77 Billion INR | 17.56% |
| 2023 Q4 | 5.6 Billion INR | -4.46% |
| 2022 Q4 | 4.85 Billion INR | 1.28% |
| 2022 Q2 | 4.52 Billion INR | 4.33% |
| 2022 FY | 18.52 Billion INR | 25.13% |
| 2022 Q1 | 4.33 Billion INR | 6.49% |
| 2022 Q3 | 4.79 Billion INR | 6.02% |
| 2021 Q3 | 3.62 Billion INR | 0.4% |
| 2021 Q1 | 3.48 Billion INR | 8.24% |
| 2021 FY | 14.8 Billion INR | 8.17% |
| 2021 Q2 | 3.61 Billion INR | 3.51% |
| 2021 Q4 | 4.07 Billion INR | 12.33% |
| 2020 Q3 | 3.58 Billion INR | 0.53% |
| 2020 Q2 | 3.56 Billion INR | 7.65% |
| 2020 Q1 | 3.31 Billion INR | 0.2% |
| 2020 FY | 13.68 Billion INR | 21.17% |
| 2020 Q4 | 3.22 Billion INR | -10.04% |
| 2019 Q3 | 2.87 Billion INR | 12.19% |
| 2019 Q1 | 2.45 Billion INR | 4.42% |
| 2019 Q4 | 3.3 Billion INR | 14.89% |
| 2019 Q2 | 2.56 Billion INR | 4.64% |
| 2019 FY | 11.29 Billion INR | 14.38% |
| 2018 Q4 | 2.34 Billion INR | -5.51% |
| 2018 Q3 | 2.48 Billion INR | -7.69% |
| 2018 Q2 | 2.69 Billion INR | 14.36% |
| 2018 FY | 9.87 Billion INR | 8.18% |
| 2018 Q1 | 2.35 Billion INR | 17.98% |
| 2017 FY | 9.12 Billion INR | 18.97% |
| 2017 Q4 | 1.99 Billion INR | -8.72% |
| 2017 Q3 | 2.18 Billion INR | -20.22% |
| 2017 Q2 | 2.73 Billion INR | 23.86% |
| 2017 Q1 | 2.21 Billion INR | 19.65% |
| 2016 Q3 | 2.15 Billion INR | 19.3% |
| 2016 Q2 | 1.8 Billion INR | -3.38% |
| 2016 Q1 | 1.86 Billion INR | -11.17% |
| 2016 Q4 | 1.84 Billion INR | -14.17% |
| 2016 FY | 7.67 Billion INR | -14.12% |
| 2015 Q2 | 2.55 Billion INR | 21.59% |
| 2015 FY | 8.93 Billion INR | 12.13% |
| 2015 Q3 | 2.17 Billion INR | -14.92% |
| 2015 Q4 | 2.1 Billion INR | -3.3% |
| 2015 Q1 | 2.1 Billion INR | 23.24% |
| 2014 Q1 | 2.02 Billion INR | 29.67% |
| 2014 Q4 | 1.7 Billion INR | -20.05% |
| 2014 Q3 | 2.13 Billion INR | 1.34% |
| 2014 FY | 7.96 Billion INR | 26.46% |
| 2014 Q2 | 2.1 Billion INR | 3.99% |
| 2013 Q4 | 1.56 Billion INR | -7.52% |
| 2013 Q3 | 1.68 Billion INR | 4.6% |
| 2013 Q1 | 1.41 Billion INR | 13.83% |
| 2013 FY | 6.29 Billion INR | 43.7% |
| 2013 Q2 | 1.61 Billion INR | 14.41% |
| 2012 Q1 | 946.42 Million INR | 0.0% |
| 2012 FY | 4.38 Billion INR | 23.31% |
| 2012 Q4 | 1.23 Billion INR | 8.35% |
| 2012 Q3 | 1.14 Billion INR | 8.36% |
| 2012 Q2 | 1.05 Billion INR | 11.5% |
| 2011 FY | 3.55 Billion INR | 16.45% |
| 2010 FY | 3.05 Billion INR | -15.04% |
| 2009 FY | 3.59 Billion INR | -0.21% |
| 2008 FY | 3.6 Billion INR | 36.44% |
| 2007 FY | 2.63 Billion INR | 9.07% |
| 2006 FY | 2.41 Billion INR | -18.63% |
| 2005 FY | 2.97 Billion INR | 17.6% |
| 2004 FY | 2.52 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott India Limited | 58.48 Billion INR | 62.772% |
| Cipla Limited | 257.74 Billion INR | 91.552% |
| Gland Pharma Limited | 56.64 Billion INR | 61.562% |
| GlaxoSmithKline Pharmaceuticals Limited | 34.53 Billion INR | 36.954% |
| Kopran Limited | 6.14 Billion INR | -254.285% |
| NGL Fine-Chem Limited | 3.38 Billion INR | -542.894% |
| Pfizer Limited | 21.93 Billion INR | 0.719% |
| Sanofi India Limited | 28.51 Billion INR | 23.629% |
| SMS Pharmaceuticals Limited | 7.09 Billion INR | -206.996% |
| TTK Healthcare Limited | 7.52 Billion INR | -189.243% |